Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer, +14

Journal of Clinical Oncology

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Ian Smith, Marion Procter, Richard D. Gelber, +21

The Lancet

Breast OncologyMedicineAdjuvant ChemotherapyBreast CancerCancer Treatment +4

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

R. Jakesz, W. Jonat, Michael Gnant, +10

The Lancet

Breast OncologyMedicinePharmacologyGynecologyAdjuvant Tamoxifen +8

Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment

Ingo Diel, Erich‐Franz Solomayer, Serban Dan Costa, +5

New England Journal of Medicine

Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

Manfred Kaufmann, Gabriel N. Hortobágyi, Aron Goldhirsch, +16

Journal of Clinical Oncology

Surgical OncologyBreast OncologyMedicinePrimary SystemicCancer Management +11

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Martin Filipits, Margaretha Rudas, R. Jakesz, +24

Clinical Cancer Research

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

Gϋnter von Minckwitz, Andreas du Bois, Marcus Schmidt, +15

Journal of Clinical Oncology

From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression

Oleg Schmidt‐Kittler, Thomas Ragg, Angela Daskalakis, +13

Proceedings of the National Academy of Sciences

Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

Michael Untch, Mahdi Rezai, Sibylle Loibl, +17

Journal of Clinical Oncology

Surgical OncologyOncologyHigh Pcr RateBreast OncologyImmunology +11

Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial

Manfred Kaufmann, Emilio Bajetta, Luc Dirix, +14

Journal of Clinical Oncology